



Wyeth Pharmaceuticals

New Lane
Havant
Hampshire, PO9 2NG
Tel: +44 (0)2392 483611
Fax: +44 (0)2392 478523

N E W S R E L E A S E

Havant supplies life-saving childhood vaccine

Havant, Hampshire, 4 September 2006 - Wyeth Pharmaceuticals' site at Havant is playing a vital role in supporting the UK Department of Health's new childhood immunisation programme against life-threatening pneumococcal diseases.

Wyeth's packaging and distribution centre at New Lane, Havant is responsible for packaging and supplying every single dose of the pneumococcal conjugate vaccine, Prevenar*[▼], being used in the immunisation programme that begins on 4 September. By the end of this year Wyeth's Havant site expects to have supplied 3 million doses of the vaccine to the NHS.

"All deliveries continue to be made to schedule," said Plant Director, Jim Neville. "Packaging and distributing this vaccine is a complicated and demanding process requiring rigorous testing and quality procedures. Our ability to meet all our delivery deadlines is a great testimony to the commitment and skills of the Havant team."

Wyeth's pneumococcal conjugate vaccine, Prevenar, helps protect against life-threatening pneumococcal diseases such as meningitis, blood poisoning and serious pneumonia. It is now being offered to all babies in the UK at 2, 4 and 13[†] months of age as part of their routine vaccination schedule. In addition, all children up to two years of age are being offered the vaccine as part of a national 'catch-up' programme to ensure all babies and young children in the most vulnerable age group are offered protection.

Estimates vary but as many as 50 children under 5 years of age lose their lives each year from serious pneumococcal diseases in England & Wales each year¹, while many more are left with permanent disabilities, such as brain damage, epilepsy and deafness.



-Ends-

For further information, please contact:

Press Office
Wyeth

Tel: 01628 414825

About Wyeth

Wyeth is one of the world's leading pharmaceutical companies with a major focus on developing innovative new medicines to improve health and well-being.

In the UK, Wyeth is one of the largest pharmaceutical companies with a broad portfolio of leading products across a wide range of treatment areas, including rheumatology, gastrointestinal disease, mental health, women's healthcare, haemophilia, prostate cancer, rheumatology, infectious disease, dermatology and transplantation. Wyeth is also a major force in preventative medicine through its Wyeth Vaccines division.

Wyeth at Havant

Wyeth has been part of the Havant business community since 1957. The Havant site has a key role within Wyeth's international operations as a global centre of excellence for the packaging and distribution of some of the company's most advanced medicines and vaccines, including an advanced treatment for rheumatoid arthritis, vaccines against meningitis, and a new antibiotic.

Products are exported to over 120 markets around the world, utilising sophisticated 'cold chain' storage and distribution techniques to ensure they are maintained at the correct temperature.

In recognition of its export success, Wyeth's Havant site was the recipient of the 2005 Exporter of the Year Award in *The News* Business Excellence Awards, sponsored by Hampshire County Council.

The site has also recently been awarded eight 'Best Practice' awards from within Wyeth's own global organisation.

**Trade mark*

† The scheduled visit for the 3rd dose of Prevenar + MMR in Northern Ireland is at 15 months.

Reference

1. McIntosh EDG, Booy R. Invasive pneumococcal disease (IPD) in England and Wales - what is the true burden and what is the potential for prevention using 7 valent pneumococcal conjugate vaccine (PCV). *Arch Dis Child* 2002; 86: 403-406.